Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.

The gap between clinically assessed physical performance and objective physical activity in liver transplant candidates

Michael A. Dunn, Deborah A. Josbeno, Amy R. Schmotzer, Amit D. Tevar, Andrea F. DiMartini, Douglas P. Landsittel, Anthony Delitto – 27 June 2016 – Frailty with sarcopenia in cirrhosis causes liver transplant wait‐list attrition and deaths. Regular physical activity is needed to protect patients with cirrhosis from frailty. We subjectively assess physical performance in selecting patients for transplant listing, but we do not know whether clinical assessments reflect the extent of activity patients actually perform.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Nathalie Ganne‐Carrié, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Ghassan Riachi, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capro

Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma

Kellie Young, Maria Aguilar, Robert Gish, Zobair Younossi, Sammy Saab, Taft Bhuket, Benny Liu, Aijaz Ahmed, Robert J. Wong – 27 June 2016 – Receiving Model for End‐Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait‐list survival and probability of liver transplantation (LT). We aim to evaluate etiology‐specific disparities in MELD exception, LT wait‐list times, and post‐LT outcomes among patients with HCC listed for LT.

Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

Jérôme Dumortier, Vincent Leroy, Christophe Duvoux, Victor de Ledinghen, Claire Francoz, Pauline Houssel‐Debry, Sylvie Radenne, Louis d'Alteroche, Claire Fougerou‐Leurent, Valérie Canva, Vincent di Martino, Filomena Conti, Nassim Kamar, Christophe Moreno, Pascal Lebray, Albert Tran, Camille Besch, Alpha Diallo, Alexandra Rohel, Emilie Rossignol, Armand Abergel, Danielle Botta‐Fridlund, Audrey Coilly, Didier Samuel, Jean‐Charles Duclos‐Vallée, Georges‐Philippe Pageaux – 27 June 2016 – Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrh

Analysis of early relaparotomy following living donor liver transplantation

Takanobu Hara, Akihiko Soyama, Masaaki Hidaka, Amane Kitasato, Shinichiro Ono, Koji Natsuda, Tota Kugiyama, Hajime Imamura, Satomi Okada, Zhassulan Baimakhanov, Tamotsu Kuroki, Susumu Eguchi – 24 June 2016 – We retrospectively analyzed the causes, risk factors, and impact of early relaparotomy after adult‐to‐adult living donor liver transplantation (LDLT) on the posttransplant outcome. Adult recipients who underwent initial LDLT at our institution between August 1997 and August 2015 (n = 196) were included. Any patients who required early retransplantation were excluded.

Subscribe to